XERS Earnings Date: Nov 5, 2026 (Estimated) — Xeris Biopharma Holdings, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is XERS's next earnings date?
Xeris Biopharma Holdings, Inc. (XERS) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.03 on revenue of $101.7M.
How did XERS do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Xeris Biopharma Holdings, Inc. posted EPS of $0.00 versus the $0.01 estimate, a miss of 100.0%. Revenue was $92.1M against a $90.1M estimate. The stock's 1-day post-earnings move was -9.2%.
How much does XERS stock move after earnings?
XERS beat EPS estimates in 2 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 8.8% (up or down) in the day after earnings.
About Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | 0.01 | 0.00 | -100.00% | $92.1M | ❌ Miss | -9.25% | +4.69% | +5.92% |
| 2026-05-07 | Q1 2026 | -0.01 | 0.01 | +200.00% | $83.1M | ✅ Beat | +4.08% | +0.94% | -2.98% |
| 2026-03-02 | Q4 2025 | 0.04 | 0.06 | +50.00% | $85.8M | ✅ Beat | -1.63% | -5.07% | -8.50% |
| 2025-11-06 | Q3 2025 | 0.01 | 0.00 | -100.00% | $74.4M | ❌ Miss | -21.88% | -23.10% | -34.04% |
| 2025-03-06 | Q4 2024 | -0.02 | -0.03 | -50.00% | $60.1M | ❌ Miss | +9.55% | +21.22% | +29.44% |
| 2024-11-08 | Q3 2024 | -0.09 | -0.11 | -22.22% | $54.3M | ❌ Miss | +3.27% | -9.23% | +7.44% |
| 2024-05-09 | Q1 2024 | -0.12 | -0.14 | -16.67% | $40.6M | ❌ Miss | +1.62% | +7.03% | +25.95% |
| 2024-03-06 | Q4 2023 | -0.10 | -0.10 | +0.00% | $44.4M | ➖ Inline | -19.48% | -28.25% | -33.44% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $102.7M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Product | 88.6% | $91.0M | +34.4% | $103.5M | $57.8M | $67.7M | $74.1M |
| Keveyis | 11.4% | $11.7M | +1.7% | $24.3M | $11.4M | $11.5M | $11.9M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.